DK1392276T3 - Forstærkning af terapeutiske effekter af flerumættede fedtsyrer - Google Patents
Forstærkning af terapeutiske effekter af flerumættede fedtsyrerInfo
- Publication number
- DK1392276T3 DK1392276T3 DK02724472T DK02724472T DK1392276T3 DK 1392276 T3 DK1392276 T3 DK 1392276T3 DK 02724472 T DK02724472 T DK 02724472T DK 02724472 T DK02724472 T DK 02724472T DK 1392276 T3 DK1392276 T3 DK 1392276T3
- Authority
- DK
- Denmark
- Prior art keywords
- amplification
- fatty acids
- polyunsaturated fatty
- therapeutic effects
- cox
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0111282.0A GB0111282D0 (en) | 2001-05-09 | 2001-05-09 | Potentiation of therapeutic effects of fatty acids |
PCT/GB2002/002145 WO2002089787A1 (en) | 2001-05-09 | 2002-05-09 | Potentiation of therapeutic effects of fatty acids |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1392276T3 true DK1392276T3 (da) | 2007-05-07 |
Family
ID=9914264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK02724472T DK1392276T3 (da) | 2001-05-09 | 2002-05-09 | Forstærkning af terapeutiske effekter af flerumættede fedtsyrer |
Country Status (27)
Country | Link |
---|---|
US (2) | US20020169209A1 (zh) |
EP (1) | EP1392276B1 (zh) |
JP (1) | JP4415243B2 (zh) |
KR (1) | KR20030096355A (zh) |
CN (1) | CN1638753A (zh) |
AT (1) | ATE349207T1 (zh) |
AU (1) | AU2002255164B2 (zh) |
BR (1) | BR0209484A (zh) |
CA (1) | CA2446363A1 (zh) |
CZ (1) | CZ20032978A3 (zh) |
DE (1) | DE60217103T2 (zh) |
DK (1) | DK1392276T3 (zh) |
EE (1) | EE200300549A (zh) |
ES (1) | ES2279864T3 (zh) |
GB (1) | GB0111282D0 (zh) |
HK (1) | HK1059386A1 (zh) |
HU (1) | HUP0400010A2 (zh) |
IL (1) | IL158678A (zh) |
IS (1) | IS7004A (zh) |
MX (1) | MXPA03010185A (zh) |
NO (1) | NO20034920D0 (zh) |
PL (1) | PL367508A1 (zh) |
RU (1) | RU2003133449A (zh) |
SK (1) | SK13652003A3 (zh) |
UA (1) | UA79744C2 (zh) |
WO (1) | WO2002089787A1 (zh) |
ZA (1) | ZA200308417B (zh) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
DE10129320A1 (de) | 2001-06-19 | 2003-04-10 | Norbert Mueller | Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen |
JP2003048831A (ja) | 2001-08-02 | 2003-02-21 | Suntory Ltd | 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物 |
NL1019368C2 (nl) * | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
ITMI20020731A1 (it) * | 2002-04-08 | 2003-10-08 | Ibsa Inst Biochimique Sa | Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3 |
EP1551382A4 (en) | 2002-09-27 | 2007-01-24 | Martek Biosciences Corp | PROPHYLACTIC TREATMENT WITH DOCOSAHEXAENIC ACID FOR PATIENTS WITH SUBCLINIC INFLAMMATION |
US8617617B2 (en) * | 2002-12-10 | 2013-12-31 | Everett Laboratories, Inc. | Methods and kits for co-administration of nutritional supplements |
GB0301701D0 (en) * | 2003-01-24 | 2003-02-26 | Ensay Ltd | Psoriasis and Eicosapentaenoic acid |
US20050032892A1 (en) * | 2003-08-07 | 2005-02-10 | The Procter & Gamble Company | Compositions, kits, and methods for treating gastrointestinal conditions |
JPWO2005046668A1 (ja) * | 2003-11-14 | 2007-05-24 | 持田製薬株式会社 | 言語障害予防・治療剤 |
WO2005058878A1 (ja) * | 2003-12-16 | 2005-06-30 | Ono Pharmaceutical Co., Ltd. | 月経困難症の予防および/または治療剤 |
ES2247939B1 (es) * | 2004-08-19 | 2007-04-01 | Fernando Jose Garcia Fructuoso | Suplemento alimenticio basado en la utilizacion de acidos grasos omega-3 (dha-epa) para el tratamiento del sindrome de fatiga cronica. |
JP4993852B2 (ja) | 2004-09-17 | 2012-08-08 | サントリーホールディングス株式会社 | ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物 |
US20100021555A1 (en) * | 2004-10-15 | 2010-01-28 | Karl Geiringer | Compositions containing high omega-3 and low saturated fatty acid levels |
GB0428384D0 (en) * | 2004-12-24 | 2005-02-02 | Sla Pharma Ag | Eicosapentaenoic acid |
AU2006213085B2 (en) * | 2005-01-10 | 2011-11-24 | Regents Of The University Of California | Use of inhibitors of soluble epoxide hydrolase to synergize activity of COX and 5-LOX inhibitors |
US8324276B2 (en) | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
US9006287B2 (en) * | 2005-02-14 | 2015-04-14 | Suntory Holdings Limited | Composition comprising dihomo-γ-linolenic acid (DGLA) as active ingredient |
EP1888081B1 (en) | 2005-05-23 | 2016-12-28 | Massachusetts Institute of Technology | Compositions containing pufa and methods of use thereof |
JP5967855B2 (ja) | 2005-06-30 | 2016-08-10 | サントリーホールディングス株式会社 | 日中活動量の低下および/又はうつ症状の改善作用を有する組成物 |
ES2489741T3 (es) | 2005-07-08 | 2014-09-02 | Mochida Pharmaceutical Co., Ltd. | Composición para la prevención de la aparición de acontecimientos cardiovasculares |
US20070042008A1 (en) * | 2005-08-18 | 2007-02-22 | Bodybio, Inc. | Compositions containing phosphatidylcholine and essential fatty acids |
US20070166411A1 (en) * | 2005-12-16 | 2007-07-19 | Bristol-Myers Squibb Company | Nutritional supplement containing long-chain polyunsaturated fatty acids |
KR100697352B1 (ko) * | 2006-01-03 | 2007-03-20 | 신승종 | 층간 소음 저감 구조체 |
US7498359B2 (en) * | 2006-02-07 | 2009-03-03 | Mochida Pharmaceutical., Ltd. | Composition and method for preventing recurrence of stroke |
PL2189155T3 (pl) * | 2006-04-12 | 2016-07-29 | Unilever Nv | Doustna kompozycja o przeciwstarzeniowym działaniu na skórę |
WO2007116027A1 (en) * | 2006-04-12 | 2007-10-18 | Unilever Plc | Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin |
EP2004161B8 (en) * | 2006-04-12 | 2013-04-17 | Unilever PLC | Oral composition comprising dha and genistein for enhancing skin properties |
KR100787765B1 (ko) | 2006-11-07 | 2007-12-24 | 고려대학교 산학협력단 | 팔미트산을 포함하는 알츠하이머병의 예방 또는 치료용조성물 |
CN101631542B (zh) | 2006-12-28 | 2011-12-21 | 三得利控股株式会社 | 神经再生剂 |
US8816110B2 (en) | 2007-02-15 | 2014-08-26 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
WO2008098375A1 (en) | 2007-02-15 | 2008-08-21 | Centre De Recherche Sur Les Biotechnologies Marines | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
ES2704439T3 (es) | 2007-03-20 | 2019-03-18 | Scf Pharma Inc | Composiciones que comprenden monoglicéridos de ácidos grasos poliinsaturados o derivados de los mismos y usos de los mismos |
CA2639412A1 (en) * | 2007-09-11 | 2009-03-11 | Universite Laval | Prostaglandin e2 modulation and uses thereof |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
BRPI0817387A2 (pt) | 2007-11-02 | 2015-09-08 | Massachusetts Inst Technology | métodos de conformidade de suplementação dietária de uridina e uso dos mesmos |
WO2009099886A1 (en) * | 2008-01-31 | 2009-08-13 | Monsanto Technology Llc | Methods of improving dha deposition and related function and/or development |
EP4137128A1 (en) | 2008-09-02 | 2023-02-22 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same |
NZ594395A (en) | 2009-02-10 | 2014-01-31 | Amarin Pharmaceuticals Ie Ltd | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
MX2011011538A (es) | 2009-04-29 | 2012-06-13 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
NZ720946A (en) | 2009-04-29 | 2017-09-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
SI3318255T1 (sl) | 2009-06-15 | 2021-07-30 | Amarin Pharmaceuticals Ireland Limited | Kompozicije in metode za zdravljenje kapi pri subjektu, ki prejema sočasno zdravljenje s statinom |
CA2775339C (en) | 2009-09-23 | 2017-03-28 | Amarin Corporation Plc | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
WO2011109681A1 (en) * | 2010-03-05 | 2011-09-09 | Catabasis Pharmaceuticals, Inc. | Fatty acid cox inhibitor derivatives and their uses |
AU2011336856A1 (en) | 2010-11-29 | 2013-07-04 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
EP2540292A1 (en) * | 2011-06-28 | 2013-01-02 | Nestec S.A. | DHA and EPA in the reduction of oxidative stress |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
WO2013072767A1 (en) | 2011-11-18 | 2013-05-23 | Pronova Biopharma Norge As | Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture |
WO2013103958A1 (en) | 2012-01-06 | 2013-07-11 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
MX2020013922A (es) | 2012-06-29 | 2022-08-15 | Amarin Pharmaceuticals Ie Ltd | Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina. |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US9629820B2 (en) | 2012-12-24 | 2017-04-25 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US10123986B2 (en) | 2012-12-24 | 2018-11-13 | Qualitas Health, Ltd. | Eicosapentaenoic acid (EPA) formulations |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US9447020B2 (en) | 2013-10-31 | 2016-09-20 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
US10813894B2 (en) | 2015-02-20 | 2020-10-27 | The Regents Of The University Of California | Methods of inhibiting pain |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US10639313B2 (en) | 2017-09-01 | 2020-05-05 | Ndsu Research Foundation | Compound for inhibition of delta-5-desaturase (D5D) and treatment of cancer and inflammation |
CA3055225A1 (en) | 2018-02-07 | 2019-08-15 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
US11166933B2 (en) | 2018-05-03 | 2021-11-09 | Scf Pharma Inc. | Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof |
MA51766A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4273763A (en) * | 1978-01-23 | 1981-06-16 | Efamol Limited | Pharmaceutical and dietary compositions |
US4444755A (en) * | 1978-01-23 | 1984-04-24 | Efamol Limited | Treatment for skin disorders |
GB8302708D0 (en) * | 1983-02-01 | 1983-03-02 | Efamol Ltd | Pharmaceutical and dietary composition |
GB8507058D0 (en) * | 1985-03-19 | 1985-04-24 | Efamol Ltd | Pharmaceutical & dietary compositions |
GB8524275D0 (en) * | 1985-10-02 | 1985-11-06 | Efamol Ltd | Pharmaceutical & dietary compositions |
US5225441A (en) * | 1987-06-18 | 1993-07-06 | Block Drug Company, Inc. | Treatment of periodontal disease |
US5198468A (en) * | 1987-06-24 | 1993-03-30 | Efamol Holdings Plc | Essential fatty acid composition |
US5457130A (en) * | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
US5922345A (en) * | 1990-12-07 | 1999-07-13 | Scotia Holdings Plc | Nutrition |
US5409955A (en) * | 1993-05-13 | 1995-04-25 | Bockow; Barry I. | Compositions and methods for inhibiting uterine contractility |
US5411988A (en) * | 1993-10-27 | 1995-05-02 | Bockow; Barry I. | Compositions and methods for inhibiting inflammation and adhesion formation |
GB9403855D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
GB9403857D0 (en) * | 1994-03-01 | 1994-04-20 | Scotia Holdings Plc | Fatty acid derivatives |
US5709855A (en) * | 1995-09-22 | 1998-01-20 | Bockow; Barry I. | Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain |
US5840715A (en) * | 1995-12-11 | 1998-11-24 | Inholtra Investment Holdings & Trading, N.V. | Dietary regimen of nutritional supplements for relief of symptoms of arthritis |
US5912006A (en) * | 1996-08-28 | 1999-06-15 | Eboc, Inc. | Compositions and methods for alleviating discomforting menstrual pain |
ATE504557T1 (de) * | 2000-02-16 | 2011-04-15 | Brigham & Womens Hospital | Aspirin-ausgelöste lipidmediatoren |
-
2001
- 2001-05-09 GB GBGB0111282.0A patent/GB0111282D0/en not_active Ceased
-
2002
- 2002-04-30 US US10/134,501 patent/US20020169209A1/en not_active Abandoned
- 2002-05-09 CN CNA028125800A patent/CN1638753A/zh active Pending
- 2002-05-09 JP JP2002586922A patent/JP4415243B2/ja not_active Expired - Fee Related
- 2002-05-09 RU RU2003133449/15A patent/RU2003133449A/ru not_active Application Discontinuation
- 2002-05-09 AU AU2002255164A patent/AU2002255164B2/en not_active Expired - Fee Related
- 2002-05-09 ES ES02724472T patent/ES2279864T3/es not_active Expired - Lifetime
- 2002-05-09 DK DK02724472T patent/DK1392276T3/da active
- 2002-05-09 KR KR10-2003-7014417A patent/KR20030096355A/ko not_active Application Discontinuation
- 2002-05-09 EP EP02724472A patent/EP1392276B1/en not_active Expired - Lifetime
- 2002-05-09 IL IL158678A patent/IL158678A/en not_active IP Right Cessation
- 2002-05-09 MX MXPA03010185A patent/MXPA03010185A/es active IP Right Grant
- 2002-05-09 DE DE60217103T patent/DE60217103T2/de not_active Expired - Fee Related
- 2002-05-09 BR BR0209484-3A patent/BR0209484A/pt not_active Application Discontinuation
- 2002-05-09 SK SK1365-2003A patent/SK13652003A3/sk not_active Application Discontinuation
- 2002-05-09 PL PL02367508A patent/PL367508A1/xx not_active Application Discontinuation
- 2002-05-09 CA CA002446363A patent/CA2446363A1/en not_active Abandoned
- 2002-05-09 AT AT02724472T patent/ATE349207T1/de not_active IP Right Cessation
- 2002-05-09 EE EEP200300549A patent/EE200300549A/xx unknown
- 2002-05-09 HU HU0400010A patent/HUP0400010A2/hu unknown
- 2002-05-09 WO PCT/GB2002/002145 patent/WO2002089787A1/en active IP Right Grant
- 2002-05-09 CZ CZ20032978A patent/CZ20032978A3/cs unknown
- 2002-09-05 UA UA2003119997A patent/UA79744C2/uk unknown
-
2003
- 2003-10-29 ZA ZA200308417A patent/ZA200308417B/en unknown
- 2003-10-30 IS IS7004A patent/IS7004A/is unknown
- 2003-11-04 NO NO20034920A patent/NO20034920D0/no not_active Application Discontinuation
-
2004
- 2004-03-26 HK HK04102246A patent/HK1059386A1/xx not_active IP Right Cessation
-
2005
- 2005-05-13 US US11/128,401 patent/US20050209329A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2002089787A1 (en) | 2002-11-14 |
NO20034920D0 (no) | 2003-11-04 |
RU2003133449A (ru) | 2005-01-20 |
UA79744C2 (en) | 2007-07-25 |
ZA200308417B (en) | 2004-05-24 |
BR0209484A (pt) | 2004-07-06 |
IS7004A (is) | 2003-10-30 |
EP1392276B1 (en) | 2006-12-27 |
EP1392276A1 (en) | 2004-03-03 |
PL367508A1 (en) | 2005-02-21 |
JP4415243B2 (ja) | 2010-02-17 |
SK13652003A3 (sk) | 2004-07-07 |
KR20030096355A (ko) | 2003-12-24 |
DE60217103D1 (de) | 2007-02-08 |
CA2446363A1 (en) | 2002-11-14 |
IL158678A (en) | 2008-06-05 |
DE60217103T2 (de) | 2007-08-16 |
IL158678A0 (en) | 2004-05-12 |
HUP0400010A2 (hu) | 2004-04-28 |
ATE349207T1 (de) | 2007-01-15 |
ES2279864T3 (es) | 2007-09-01 |
CZ20032978A3 (cs) | 2004-09-15 |
JP2004537514A (ja) | 2004-12-16 |
CN1638753A (zh) | 2005-07-13 |
AU2002255164B2 (en) | 2008-09-11 |
EE200300549A (et) | 2004-02-16 |
GB0111282D0 (en) | 2001-06-27 |
HK1059386A1 (en) | 2004-07-02 |
MXPA03010185A (es) | 2004-03-16 |
US20020169209A1 (en) | 2002-11-14 |
US20050209329A1 (en) | 2005-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1392276T3 (da) | Forstærkning af terapeutiske effekter af flerumættede fedtsyrer | |
NO20026093D0 (no) | Terapeutiske kombinasjoner av fettsyrer | |
EE200300599A (et) | Koensüüm Q ja EPA või muu asendamatu rasvhape | |
CY1105119T1 (el) | Χρηση πολυακορεστων λιπαρων οξεων για την πρωτογενη προληψη σοβαρων καρδιαγγειακων επεισοδιων | |
BR0308681A (pt) | Métodos de fabricação de derivados de ácido beta-hidroxicarboxìlico | |
DE60128901D1 (de) | Beschichtungszusammensetzung zur geschmacksmaskierung | |
DK1163204T3 (da) | Lipoxinforbindelser og deres anvendelse | |
EE200300536A (et) | Farmatseutiliselt aktiivsed uridiiniestrid | |
EE200100670A (et) | Amiidasendatud imidasokinoliinid | |
AR021578A1 (es) | Formulacion en perlas de pravastatina con revestimiento enterico | |
DK1820506T3 (da) | Dipyridamol-formuleringer med forlænget frigivelse og fremgangsmåde til fremstilling heraf | |
RS50713B (sr) | Farmaceutska kompozicija koja sadrži inhibitor lipaze i saharozni estar masne kiseline | |
AR021934A1 (es) | Composicion de administracion oral con liberacion controlada de al menos un analgesico | |
AU2003301584A1 (en) | Enzyme-catalyzed transesterifications of pendant carboxylic acid groups | |
DE502004003952D1 (de) | Enzymatische herstellung von (meth)acrylsäureestern | |
AU2003294916A1 (en) | Use of cis-99, trans-11 isomer of conjugated linoleic acid (cla) for treating inflammatory diseases | |
AU5873400A (en) | spla2 inhibitors | |
GT200600403A (es) | Composiciones y formas de dosificacion farmaceuticas | |
AU7053700A (en) | Novel spla2 inhibitors | |
DE60112578D1 (de) | Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase | |
BRPI0415428A (pt) | formulações terapêuticas | |
WO2002080974A1 (fr) | Utilisation medicale d'inhibiteur de production de cytokine | |
AR021830A1 (es) | Utilizacion de acido docosahexaenoico y acido araquidonico para mejorar el crecimiento de bebes anteriores a termino | |
UY27321A1 (es) | Nueva composición farmacéutica |